1215746-83-0Relevant articles and documents
Synthesis and Biological Evaluation of Oxygen-containing Heterocyclic Ring-fused 23-Hydroxybetulinic Acid Derivatives as Antitumor Agents
Zhang, Hengyuan,Li, Fangzheng,Zhu, Peiqing,Liu, Jie,Yao, Hequan,Jiang, Jieyun,Ye, Wencai,Wu, Xiaoming,Xu, Jinyi
, p. 424 - 431 (2015)
A collection of isoxazole and oxadiazole substituted 23-hydroxybetulinic acid (HBA) derivatives were designed, synthesized and evaluated for their antitumor activity. Most of the newly synthesized compounds exhibited more potent antiproliferative activity than patent compound 23-hydroxybetulinic acid, especially 13e and 14a were about four- to sevenfold more potent against all tested cancer cell lines than 23-hydroxybetulinic acid. Furthermore, the in vivo antitumor activity of 13e and 14a was validated in H22 liver cancer and B16 melanoma xenograft mouse models. The structure-activity relationships of these 23-hydroxybetulinic acid derivatives were also discussed based on the present investigation.
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives
Zhang, Hengyuan,Zhu, Peiqing,Liu, Jie,Lin, Yan,Yao, Hequan,Jiang, Jieyun,Ye, Wencai,Wu, Xiaoming,Xu, Jinyi
, p. 728 - 732 (2015)
A collection of pyrazole-fused 23-hydroxybetulinic acid derivatives were designed, synthesized and evaluated for their antitumor activity. Most of the newly synthesized compounds exhibited significant antiproliferative activity. Especially compound 15e displayed the most potent activity with the IC50 values of 5.58 and 6.13 μM against B16 and SF763 cancer cell lines, respectively. Furthermore, the significant in vivo antitumor activity of 15e was validated in H22 liver cancer and B16 melanoma xenograft mouse models. The structure-activity relationships of these 23-hydroxybetulinic acid derivatives were also discussed based on the present investigation.
23-hydroxybetulinic acid 3-site modified derivative, and preparation method and application thereof
-
Paragraph 0046-0049, (2021/08/07)
The invention discloses a 23-hydroxybetulinic acid 3-site modified derivative, and a preparation method and application thereof. According to the invention, new drug molecules are found based on structural modification of natural products, and aliphatic side chains with different sizes, benzene rings substituted by different groups at different positions and nitrogen-containing heterocyclic ring substituents are introduced through derivatization of C3-site hydroxyl, so that a novel antitumor compound with relatively good activity is obtained.
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies
Yao, Hong,Wei, Guoxiang,Liu, Yanpeng,Yao, Hequan,Zhu, Zheying,Ye, Wencai,Wu, Xiaoming,Xu, Jinyi,Xu, Shengtao
supporting information, p. 1030 - 1034 (2018/10/15)
23-Hydroxybetulinic acid (23-HBA) is a complex lupane triterpenoid, which has attracted increasing attention as an anticancer agent. However, its detailed mechanism of anticancer action remains elusive so far. To reveal its anticancer mode of action, a series of fluorescent 23-HBA derivatives conjugated with coumarin dyes were designed, synthesized, and evaluated for their antiproliferative activities. Subcellular localization and uptake profile studies of representative fluorescent 23-HBA probe 26c were performed in B16F10 cells, and the results suggested that probe 26c was rapidly taken up into B10F10 cells in a dose-dependent manner and mitochondrion was the main site of its accumulation. Further mode of action studies implied that the mitochondrial pathway was involved in 23-HBA-mediated apoptosis. Together, our results provided new clues for revealing the molecular mechanism of natural product 23-HBA for its further development into an antitumor agent.
